<DOC>
	<DOCNO>NCT00002312</DOCNO>
	<brief_summary>To evaluate pharmacokinetics , safety , tolerance delavirdine mesylate ( U-90152 ) multiple dos give orally asymptomatic HIV-1 positive patient maintain stable dose zidovudine ( AZT ) . To investigate optimum dose regimen U-90152 give average trough concentration &gt; 1 micromolar combination standard AZT therapy , examine drug interaction two drug . To establish MTD U-90152 HIV-1 positive patient stable AZT therapy . To investigate comparative pharmacokinetics HIV-1 positive men woman .</brief_summary>
	<brief_title>The Safety Effectiveness U-90152 HIV-1 Infected Patients Who Take Zidovudine</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Inhaled pentamidine follow completion inpatient pharmacokinetic portion study . Patients must : HIV1 infection . CD4 count 200 500 cells/mm3 . Maintenance AZT least 6 week . No active opportunistic infection . Ability swallow numerous tablet without difficulty . Ability blood sample draw . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute medical problem , include opportunistic infection ( active cryptococcosis , pneumocystis carinii , herpes zoster , histoplasmosis , CMV ) nonopportunistic disease ( liver renal disease , orthostatic hypotension , hypertension , progressive multifocal leukoencephalopathy , lymphoma , Kaposi 's sarcoma , malignancy ) . Clinically significant hypersensitivity piperazine type drug ( Antepar , Stelazine , U87201E ) . Negative EMIT drug screen equivalent drug abuse . Concurrent Medication : Excluded : Antiretroviral agent AZT . Primary secondary prophylactic medication opportunistic infection ( inhaled pentamidine permit follow completion inpatient pharmacokinetic portion study ) . Patients follow prior condition exclude : History clinically significant nervous system muscle disease , seizure disorder , AIDS dementia , psychotic disorder might impair study compliance . History clinically significant cardiovascular , renal , hepatic , cardiac , pulmonary , endocrine , hematologic , vascular , collagen disease . Prior Medication : Excluded : Prior U87201E nonnucleoside reverse transcriptase inhibitor ( nevirapine , TIBO , Ldrugs , HEPT ) . Antiretroviral agent ( AZT ) immunomodulating agent within 15 day prior study entry . Primary prophylactic drug within 15 day prior study entry . Any known enzymeinducing drug enzymeinhibiting agent , ketoconazole , fluconazole , rifampin , isoniazid , cimetidine , within 15 day prior study entry . Any investigational medication within 15 day prior study entry . Unwilling comply safer sex practice . Active substance abuse . Alcohol consumption inpatient pharmacokinetic portion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1994</verification_date>
	<keyword>Drug Interactions</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>